To generate energy efficiently, the cell is uniquely challenged to co-ordinate the abundance of electron transport chain protein subunits expressed from both nuclear and mitochondrial genomes.
Introduction
In eukaryotes, coupling of the mitochondrial electron transport chain to oxidative phosphorylation generates the majority of ATP that fulfils cellular energy requirements. The first enzyme of the electron transport chain, NADH:ubiquinone oxidoreductase (complex I), catalyses the transfer of electrons from NADH to coenzyme Q10, pumps protons across the inner mitochondrial membrane and produces reactive oxygen species (ROS). Mammalian mitochondrial complex I dynamically incorporates 45 distinct subunits into a ~1 MDa mature structure [1, 2] . It is known that oxidatively damaged subunits can be exchanged in the intact holo-enzyme [3] , but how this process may be regulated is poorly understood. The efficiency and functional integrity of OXPHOS are thought to be partly maintained through a combination of tightly co-ordinated transcriptional and posttranscriptional regulation [4] [5] [6] and specific sub-cytoplasmic co-localisation [7, 8] . The nuclear encoded subunits are imported into the mitochondria after translation in the cytoplasm and their complexes assembled together with the mitochondrially encoded subunits in an intricate assembly process [9] [10] [11] . Mitochondrial biogenesis is co-ordinated first transcriptionally from both genomes [12] , and then post-transcriptionally by regulatory small noncoding RNAs such as microRNAs (miRNAs) [13, 14] . Recently, SAMMSON a long noncoding RNA (lncRNA) was found to bind p32 and, within mitochondria, enhanced the expression of mitochondrial genome-encoded polypeptides [15] .
Nuclear-encoded and cytosol-located lncRNAs have not yet been implicated in regulating mitochondrial OXPHOS [16] despite being surprisingly numerous and often found localised to mitochondrion-and ribosome-adjacent portions of the rough endoplasmic reticulum [17] . It is here, on the ribosome, that turnover of miRNA-targeted mRNAs frequently occurs during their translation [18] . Here we describe a novel mammalian conserved lncRNA, termed Cerox1 (cytoplasmic endogenous regulator of oxidative phosphorylation 1). Cerox1 regulates complex I activity in both mouse and human cells by co-ordinately regulating the abundance of at least 12 complex I transcripts via a miRNA-mediated mechanism. Cerox1 knockdown decreases the enzymatic activities of complexes I and IV. Conversely, elevation of Cerox1 levels increases their enzymatic activities, halves cellular oxidative stress, and protects cells against the cytotoxic effects of the complex I inhibitor rotenone. To our knowledge, Cerox1 is the first lncRNA modulator of normal mitochondrial energy metabolism homeostasis and cellular redox state. The miRNA-dependency of Cerox1 and the regulation of associated OXPHOS transcripts are supported by: (i) direct physical interaction of miR-488-3p with Cerox1 and complex I transcripts; (ii) decrease or increase in Cerox1 and complex I transcripts following miR-488-3p overexpression or inhibition, respectively; (iii) miR-488-3p destabilisation of wildtype Cerox1, but not a Cerox1 transcript containing a mutated miR-488-3p MRE seed region; and, (iv) absence of the OXPHOS phenotypes either in cell lines deficient in microRNA biogenesis or when Cerox1's predicted miR-488-3p response element is mutated. The miRNA-dependent role of Cerox1 illustrates how RNA-interaction networks can regulate OXPHOS and that lncRNAs represent novel targets for modulating OXPHOS enzymatic activity.
RESULTS

Cerox1 is a conserved, ubiquitously expressed long noncoding RNA
Cerox1 was selected for further investigation from among a set of central nervous system-derived polyadenylated long non-coding RNAs identified by cDNA sequencing (GenBank Accession AK079380, 2810468N07Rik) [19, 20] . Mouse Cerox1 is a 1.2 kb, two exon, intergenic transcript which shares a bidirectional promoter with the SRY (sex determining region Y)-box 8 (Sox8) gene (Fig. 1a ).
Cerox1 exons are conserved among eutherian mammals but not with non-eutherian vertebrates (Fig.   1a ). A human orthologous transcript (CEROX1, GenBank Accession BC098409) was identified by sequence similarity and conserved synteny (60-70% nucleotide identity within alignable regions, Fig. 1b,c). Both mouse and human transcripts have low coding potential (Methods, Supplementary Fig.   1a ) and no evidence for translation from available proteomic datasets.
Cerox1 expression in primary tissues and cells is exceptionally high, within the top 13% of a set of 879 lncRNAs with associated cap analysis of gene expression (CAGE) clusters ( Fig. 1d,e ). Expression is particularly high in neuroglia and in neural progenitor cells [21] [22] [23] , with expression in brain being higher than 64% of all protein coding genes (Fig. 1d ). This high expression ( Fig. 1e ) was confirmed using quantitative real-time PCR (qPCR) for both mouse and human orthologous transcripts ( Supplementary Fig. 1b, c) . In mouse neuroblastoma (N2A) cells the most highly expressed Cerox1 transcript ( Supplementary Fig. 1d , e) is strongly enriched in the cytoplasmic fraction ( Fig. 1f ) with a short half-life of 36 ± 16 mins ( Supplementary Fig. 1f ) and is mainly associated with the ribosomefree fraction ( Supplementary Fig. 1g ).
Cerox1 expression modulates levels of oxidative phosphorylation transcripts
Decreasing or increasing Cerox1 expression in N2A cells had no effect on the expression of neighbouring genes ( Supplementary Fig. 2a ). In contrast, Cerox1 overexpression led to differential expression of 286 distal genes (q < 0.05, Bonferroni multiple testing correction; Supplemental Table   1 ), of which an unexpectedly large majority (83%; 237) were upregulated (P < 10 -6 ; binomial test).
Our attention was immediately drawn to mitochondrial respiratory chain genes because these were considerably (≥20-fold) and significantly enriched among the set of upregulated genes ( Fig. 2a ).
The mitochondrial electron transport chain (ETC) consists of five multi-subunit complexes encoded by approximately 100 genes of which only 13 are located in the mitochondrial genome. All 15 ETC transcripts that show statistically significant differential expression after Cerox1 overexpression are nuclear encoded (Fig. 2b,c) with the greatest changes observed by qPCR for complex I subunit transcripts ( Supplementary Fig. 2b ). Twelve of 35 nuclear encoded complex I subunits or assembly factors transcripts increased significantly (>40%) following Cerox1 overexpression; we consider these to be gene expression biomarkers for Cerox1 activity in the mouse N2A system (Fig. 2c ). In the reciprocal Cerox1 knock-down experiment, all 12 were reduced in abundance, 8 significantly ( Supplementary Fig. 2c ). Taken together, these results indicate that Cerox1 positively and coordinately regulates the levels of many mitochondrial complex I transcripts.
Increased abundance of OXPHOS subunit transcripts, following Cerox1 overexpression, was found to elevate protein levels. Western blots using reliable antibodies for the key complex I catalytic core proteins NDUFS1 and NDUFS3, showed approximately 2.0-fold protein level increases that surpassed their ~1.4-fold transcript level changes ( Fig. 2d ). Cerox1 transcript abundance is thus coupled positively to OXPHOS transcript levels and to their availability for translation, resulting in an amplification of the amount of protein produced.
Cells overexpressing Cerox1 exhibited a reduction in cell cycle activity, without deviating from normal cell cycle proportions ( Supplementary Fig. 2d,e ). Cerox1 levels thus affect the timing of cell division.
Cerox1 can regulate mitochondrial OXPHOS enzymatic activity
Increased translation of some complex I transcripts leads to increased respiration [24] or, more specifically, an increase in the enzymatic activity of complex I [25] . Indeed, complex I and complex IV enzymatic activities increased significantly after Cerox1 overexpression (by 22%, P = 0.01; by 30%, P = 0.003, respectively; 2-tailed Student's t-test) and oxygen consumption increased ( Fig. 3a,b ). These moderate increases in enzyme activities are likely to produce substantial increases beyond the already very high basal rate of ATP formation [26] . Conversely, after Cerox1 knockdown complex I and complex IV enzymatic activities decreased significantly (by 11%, P = 0.03 and 19%, P = 0.02, respectively), with Cerox1 knockdown cells consuming less oxygen ( Fig. 3c,d ). These observed increases in enzymatic activity were not due to changes in mitochondria number because the enzymatic activities of complexes II, III and citrate synthase ( Fig. 3a,b) , and the mitochondrial-tonuclear genome ratio all remained unaltered by changes in Cerox1 levels ( Supplementary Fig. 3a, b ).
These data indicate that Cerox1 can specifically regulate the catalytic activities of complex I and complex IV in mouse N2A cells.
Cerox1 expression can protect cells from oxidative stress
Complex I deficient patient cells experience increased ROS production [27] . In Cerox1 knockdown N2A cells we found ROS levels to have increased significantly, by almost 20% (Fig. 4a ). Conversely, in cells overexpressing Cerox1, ROS production was nearly halved (Fig. 4a ), and protein carbonylation, a measure of ROS-induced damage, was reduced by 35% in Cerox1-overexpressing cells (Fig. 4b) . The observed Cerox1-dependent decrease in ROS levels is of particular interest because mitochondrial complex I is a major producer of ROS which triggers cellular oxidative stress and damage, and an increase in ROS production is a common feature of mitochondrial dysfunction in disease [28] .
We next demonstrated that Cerox1-induced increases in complex I and complex IV activities protect cells against the deleterious effects of specific mitochondrial complex inhibitors, specifically rotenone and sodium azide (complex I and complex IV inhibitors, respectively); conversely, Cerox1knockdown cells were significantly more sensitive to rotenone (P < 1x10 -3 , Fig. 4c ). Cells overexpressing Cerox1 and treated with rotenone, a complex I inhibitor, exhibited no significant difference in protein carbonylation (data not shown). From these results we conclude that increased Cerox1 expression leads to decreased ROS production, decreased levels of oxidative damage to proteins and can confer protective effects against complex I and complex IV inhibitors.
Increased OXPHOS enzymatic activity is dependent upon miRNA binding to Cerox1
Due to their positive correlation in expression and cytoplasmic localisation we next considered whether Cerox1 regulates complex I transcripts post-transcriptionally by competing with them for the binding of particular miRNAs. To address this hypothesis, we took advantage of mouse Dicerdeficient (Dicer / ) embryonic stem cells that are deficient in miRNA biogenesis [29] . In wildtype mouse ES cells Cerox1 overexpression again positively correlated with transcript levels of six complex I subunits ( Fig. 5a ), of which four had previously shown significant changes in N2A cells after Cerox1 overexpression ( Fig. 2c ). In contrast, overexpression in Dicer / cells did not lead to an increase in the level of these transcripts (Fig. 5a ). These results indicate that Cerox1's ability to alter mitochondrial metabolism is miRNA-dependent.
Four specific miRNA families (miR-138-5p, miR-28/28-5p/708-5p, miR-370-3p, and miR-488-3p; Supplementary Fig. 4a ) were selected for further investigation based on the conservation of their predicted binding sites (miRNA recognition elements, MREs) in both mouse Cerox1 and human CEROX1 ( Fig. 5b ). All MREs conserved in mouse Cerox1 and human CEROX1 for N2A-expressed miRNAs ( Fig. 5b) were mutated by inversion of all five seed regions. This mutated Cerox1 transcript failed to alter either complex I transcript levels or enzyme activities when overexpressed ( Fig. 5c, d) indicating that its molecular effects are mediated by one or more of these MREs.
We then overexpressed each of the four miRNAs in N2A cells which each caused a reduction in Cerox1 levels ( Fig. 5e ). Overexpression of the tissue-restricted miRNA miR-488-3p ( Supplementary   Fig. 4b , [30] ) resulted in the greatest depletion of the Cerox1 transcript ( Fig. 5e ), indicating that this MRE is likely to be physiologically relevant [31] .
Cerox1 activity is mediated by miR-488-3p
Our previous results showed that Cerox1 abundance modulates complex I activity and transcripts (Figs. [2] [3] [4] and that miR-488-3p has the greatest effect in decreasing Cerox1 transcript levels ( Fig. 5e ).
To determine whether miR-488-3p modulates complex I transcript levels we overexpressed and inhibited miR-488-3p in N2A cells ( Fig. 6a,b ). Results showed that miR-488-3p modulates these transcripts' levels, with overexpression leading to a significant downregulation of all 12 Cerox1sensitive complex I transcripts ( Fig. 6a ), whilst, conversely, miR-488-3p inhibition leads to increased expression ( Fig. 6b ).
To determine whether the single predicted miR-488-3p MRE in Cerox1 is required to exert its effects on complex I we created a Cerox1 transcript containing three mutated nucleotides in this MRE ( Fig.   6c ). As expected for a bona fide MRE, these substitutions abrogated the ability of miR-488-3p to destabilise Cerox1 transcript ( Fig. 6d ). Importantly, these substitutions also abolished the ability of Cerox1, when overexpressed, to elevate complex I transcript levels (Fig. 6e ), and to enhance complex I enzymatic activity (Fig. 6f ). The latter observation is important because not all bona fide miRNAtranscript interactions are physiologically active [31] . Finally, direct interaction between Cerox1 and miR-488-3p was confirmed by pulling-down transcripts with biotinylated miR-488-3p ( Fig. 6g ). This experiment also identified 9 of 10 complex I transcripts tested as direct targets of miR-488-3p
binding. These included transcripts not predicted as containing a miR-488-3p MRE, as expected from the high false negative rate of MRE prediction algorithms [32] [33] [34] . As expected, the two negative control transcripts, which are not responsive to Cerox1 transcript levels, and have no predicted MREs for miR-488-3p failed to bind miR-488-3p.
Considered together, these findings indicate that: (i) Cerox1 can post-transcriptionally regulate OXPHOS enzymatic activity as a miRNA decoy, and (ii) of 12 miR-488-3p:Nduf subunit interactions that were investigated, all 12 are indicated either by responsiveness to miR-488-3p through miRNA overexpression or inhibition ( Fig. 6a,b ), or by direct interaction with a biotinylated miR-488-3p mimic ( Fig. 6f ). Consequently, our data demonstrates that miR-488-3p directly regulates the transcript levels of Cerox1 and at least 12 nuclear encoded mitochondrial complex I subunit genes (31% of all) and indirectly modulates complex I activity ( Fig. 6h ) in N2A cells.
Cerox1 is an evolutionarily conserved regulator of mitochondrial complex I activity
Fewer than 20% of lncRNAs are conserved across mammalian evolution [35] and even for these functional conservation has rarely been investigated. In our final set of experiments we demonstrated that CEROX1, the orthologous human transcript, is functionally equivalent to mouse Cerox1 in regulating mitochondrial complex I activity. Similar to mouse Cerox1, human CEROX1 is highly expressed in brain tissue, is otherwise ubiquitously expressed ( Supplementary Fig. 1b ), and is enriched in the cytoplasm (Fig. 7a ). CEROX1 is expressed in human tissues at unusually high levels: it occurs among the top 0.3% of all expressed lncRNAs ( Fig. 7b ) and its average expression is higher than 87.5% of all protein coding genes [36] . Its expression is highest within brain tissues, particularly within the basal ganglia and cortex ( Fig. 7c ).
Importantly, following CEROX1 overexpression in human embryonic kidney (HEK293T) cells mitochondrial complexes' I and III activities increased significantly ( Fig. 7d ). CEROX1 overexpression had a greater effect on complex I activity than the mouse orthologous sequence and also increased the activity of complex III, rather than complex IV activity, in these cells. The latter distinction could reflect the differences in miRNA pools between mouse and human cell lines and/or the presence of different MREs in the lncRNA and human OXPHOS transcripts.
Strikingly, either reciprocal expression of mouse Cerox1 in human HEK293T cells or human CEROX1
in mouse N2A cells, recapitulates the previously observed increase in complex I activity (Fig. 7e ). The role of both Cerox1 and CEROX1 in modulating the activity of mitochondrial complex I has thus been conserved over 90 million years since the last common ancestor of mouse and human.
DISCUSSION
Cerox1 is the first evolutionarily conserved lncRNA to our knowledge that has been demonstrated experimentally to regulate mitochondrial energy metabolism. Its principal location in N2A cells is in the cytoplasm where it post-transcriptionally regulates the levels of mitochondrial OXPHOS subunit transcripts and proteins by decoying for miRNAs ( Supplementary Fig. 5 ), most particularly miR-488-3p. This microRNA shares with Cerox1 an early eutherian origin, and enhanced expression in brain samples [30] . Changes in Cerox1 abundance in vitro alter mitochondrial OXPHOS subunit transcript levels and, more importantly, elicit larger changes in their protein subunits levels, leading to substantial changes in mitochondrial complex I catalytic activity. The observed changes in catalytic activity are in line with the degree of change seen in diseases exhibiting mitochondrial dysfunction for example [37] [38] [39] . Overexpression of Cerox1 in N2A cells increases oxidative metabolism, halves cellular oxidative stress and enhances protection against the complex I inhibitor rotenone. The effect of Cerox1 on complex I subunit transcript levels can be explained by their sharing MREs with Cerox1, and subsequent competition for miRNA binding, most notably for miR-488-3p, which buffers the OXPHOS transcripts against miRNA-mediated repression.
Multiple RNA transcripts have been experimentally shown to compete with mRNAs for binding to miRNAs, thereby freeing the protein coding mRNA from miRNA-mediated repression [40] [41] [42] [43] [44] [45] . It has been experimentally demonstrated that this miRNA:RNA regulatory crosstalk can initiate rapid coordinate modulation of transcripts whose proteins participate within the same complex or process [45] . Physiological relevance of this crosstalk mechanism remains incompletely understood.
Furthermore, mathematical modelling [46] [47] [48] and experimental investigation [49, 50] of the dynamics and mechanism of endogenous transcript competition for miRNA binding have resulted in contrasting conclusions. Current mathematical models do not take full account of miRNA properties, such as the repressive effect not being predictable from its cellular abundance [51] , intracellular localisation such as at the rough ER [52] , loading on the RNA-induced silencing complex The conclusions of experiments have also assumed that all miRNA target transcripts that contain the same number and affinity of miRNA binding sites are equivalent, that steady-state measurements are relevant to repression dynamics, and that observations for one miRNA in one experimental system are equally applicable to all others [53] .
Considered together, our lines of experimental evidence indicate that miRNA-mediated target competition by Cerox1 substantially perturbs a post-transcriptional gene regulatory network that includes at least 12 complex I subunit transcripts. This is consistent with the expression level of miR-488-3p [54] and the high in vivo expression of both Cerox1 and OXPHOS transcripts [55, 56] . Human CEROX1 levels, for example, exceed those of all complex I subunit transcripts (those in Fig. 6a ) in both newly-formed and myelinating oligodendrocytes [57] . High levels of Cerox1 in the central nervous system support the notion that Cerox1 maintains OXPHOS homeostasis in cells with sustained high metabolic activity and high energy requirements [58] .
Our experiments demonstrate that post-transcriptional regulation of a subset of complex I subunits by Cerox1 leads to elevated oxygen consumption. How consumption increases when there is a higher abundance of only a subset of OXPHOS transcripts remains unclear. However, this phenomenon has been observed previously in mouse dopaminergic neurons [25] and primary mouse embryonic fibroblasts and pinnal tissues [24]. Our observation of increased enzymatic activity may relate to the formation, by the complexes of the respiratory chain, of higher order supercomplexes [59, 60] . Alternatively, the observed increases in OXPHOS activity may reflect some subunits of the complex I holo-enzyme (including NDUFS3 and NDUFA2) being present as a monomer pool and therefore being available for direct exchange without integration into assembly intermediates [3] . This monomer pool facilitates the rapid swapping out of oxidatively damaged complex I subunits [3] . It is thus possible that Cerox1-mediated expansion of the monomer pool thereby improves complex I catalysis efficiency (Supplemental Fig. 5 ).
More efficient ETC enzymatic activity might be relevant to mitochondrial dysfunction, a feature of many disorders that often manifests as decreases in the catalytic activities of particular mitochondrial complexes. A decrease in catalytic activity can result in elevated ROS production, leading to oxidative damage of lipids, DNA, and proteins, with OXPHOS complexes themselves being particularly susceptible to such damage [61] . Parkinson's and Alzheimer's diseases both feature pathophysiology associated with oxidative damage resulting from increased ROS production and decreased complex I and IV activities (a reduction of 30% and 40%, respectively) [37, 62, 63] .
Currently no effective treatments exist that help to restore mitochondrial function. It has been demonstrated that a 20% increase in complex I activity protects mouse midbrain dopaminergic neurons against MPP+, a complex I inhibitor and a chemical model of Parkinson's disease [25] . We note that highest expression of CEROX1 occurs in the basal ganglia, which contains the substantia nigra in which the dopaminergic neurons that are particularly sensitive to degeneration in Parkinson's disease are located. CEROX1's ability to increase mitochondrial complex I activity might be recapitulated pharmacologically to restore mitochondrial function, as an exemplar of therapeutic upregulation of gene expression [64] .
MATERIALS AND METHODS
Gene expression profiling
The lncRNA transcripts were assessed for coding potential using the coding potential calculator [65] , in triplicate using gene specific primers. Multiple reference genes were assessed for lack of variability using geNorm [70] . Human expression data were normalised to TUBA1A and POLR2A, whilst mouse expression data were normalised to Tbp and Polr2a.
Tissue culture and flow cytometry
Mouse Neuro-2a neuroblastoma cells (N2A) and human embryonic kidney (HEK293T) cells were grown at 37 O C in a humidified incubator supplemented with 5% CO2. Both cell lines were grown in Dulbecco's modified Eagle medium containing penicillin/streptomycin (100 U/ml, 100 ug/ml respectively) and 10% fetal calf serum. Cells were seeded at the following densities: 6 well dish, 0.3
x 10 6 ; 48 well dish, 0.2 x 10 4 ; T75 flask 2.1 x 10 6 . Mouse embryonic stem cells and dicer knock-out embryonic stem cells were maintained as described previously [29] . Cells were counted using To determine the stability of the lncRNA transcripts, cells were cultured to ~50 % confluency and then transcription was inhibited by the addition of 10 g/ml actinomycin D (Sigma) in DMSO.
Control cells were treated with equivalent volumes of DMSO. Transcriptional inhibition of the N2A cells was conducted for 16 hours with samples harvested at 0 hrs, 30 mins, 1 hr, 2 hrs, 4 hrs, 8 hrs and 16 hrs. RNA samples for fractionation and turnover experiments were collected in Trizol (Invitrogen) and RNA purified and DNAse treated using the RNeasy mini kit (Qiagen). Reverse transcription for cellular localisation and turnover experiments was performed as described earlier.
Constructs and biotinylated miRNAs
PCR primers modified to contain BglII and XhoI sites were used to amplify the full length mouse Cerox1, whilst human CEROX1 and the mouse 5x MRE mutant were synthesised by Biomatik (Cambridge, Ontario), and also contained BglII and XhoI sites at the 5' and 3' ends respectively. All other MRE mutants were produced using overlapping PCR site directed mutagenesis to mutate 3 bases of the miRNA seed region. All purified products were ligated into the prepared backbone and then transformed by heat shock into chemically competent DH5, and plated on selective media. Transcripts for the luciferase destabilisation assays were cloned into the pmirGLO miRNA target expression vector (Promega) and assayed using the dual-luciferase® reporter assay system (Promega). miRCURY LNA biotinylated miRNAs (mmu-miR-488-3p and mmu-negative control 4)
were purchased from Exiqon, and direct mRNA-miRNA interactions were detected using a modified version of [72] and enrichment of targets was detected by qPCR.
Computational techniques
MREs were predicted using TargetScan v7.0 in both the 3'UTR (longest annotated UTR, ENSEMBL build 70) or the full length transcript of protein coding genes, and across the entire transcript for lncRNAs. The average expression across 46 human tissues and individuals according to the Pilot 1 data from the GTEx Consortium [73] was computed for both protein-coding genes and intergenic lncRNAs from the Ensembl release 75 annotation [74] . We used the normalized number of CAGE tags across 399 mouse cells and tissues from the FANTOM5 Consortium (http://fantom.gsc.riken.jp) [75] as an approximation of expression levels for protein-coding genes and intergenic lncRNAs from the Ensembl release 75 annotation. If multiple promoters were associated with a gene, we selected the promoter with the highest average tag number. Conserved sequence blocks in the lncRNA sequences were identified using LALIGN [76] .
Microarray analysis
Microarray analysis was performed on 16 samples (four overexpression/four overexpression controls; four knock-down/four knock-down controls), and hybridizations were performed by the OXION array facility (University of Oxford). Data were analysed using the web-based Bioconductor interface, CARMAweb [77] . Differentially expressed genes (Bonferroni corrected P-value <0.05) were identified between mouse lncRNA overexpression and control cells using Limma from the Bioconductor package between the experimental samples and the respective controls. Microarray data are accessible through ArrayExpress, accession E-MATB-6792.
Western blots
Total protein was quantified using a BCA protein assay kit (Pierce). anti-NDUFS1 (rabbit monoclonal, ab169540, 1:30,000), anti-NDUFS3 (mouse monoclonal, 0.15 mg/ml, ab110246), or anti-alpha tubulin loading control (mouse monoclonal, ab7291, 1:30,000).
Following incubation with the primary antibodies, blots were washed 3 x 5 min, and 2 x 15 mins in TBS-T and incubated with the appropriate secondary antibody for 1 hour at room temperature: goat anti-rabbit HRP (Invitrogen) 1:30,0000; goat anti-mouse HRP (Dako) 1:3,000. After secondary antibody incubations, blots were washed and proteins of interested detected using ECL prime chemiluminescent detection reagent (GE Healthcare) and the blots imaged using an ImageQuant LAS 4000 (GE Healthcare). Signals were normalised to the loading control using ImageJ [78] .
Oxidative phosphorylation enzyme assays and oxygen consumption
Cell lysates were prepared 48 hours post-transfection, by harvesting cells by trypsinisation, washing three times in ice cold phosphate buffered saline followed by centrifugation to pellet the cells (2 mins, 1000 g). Cell pellets were resuspended to homogeneity in KME buffer (100 mM KCl, 50 mM MOPS, 0.5 mM EGTA, pH 7.4) and protein concentrations were determined using a BCA protein assay detection kit (Pierce). Cell lysates were flash frozen in liquid nitrogen, and freeze-thawed three times prior to assay. 300-500 g of cell lysate was added per assay, and assays were normalised to the total amount of protein added.
All assays were performed using a Shimadzu UV-1800 spectrophotometer, absorbance readings 
Oxidative stress measurements
Hydrogen peroxide production was assessed as a marker of reactive oxygen species generation using the fluorescent indicator Amplex Red (10 M, Invitrogen) in combination with horseradish peroxidise (0.1 units ml -1 ). Total amount of H2O2 produced was normalised to mg of protein added.
Protein carbonylation was assessed using the OxyBlot protein oxidation detection kit (Merck Millipore), and differential carbonylation was assessed by densitometry. The cell stress assay was performed on cells seeded in 48 well plates, and assayed 12 hours later by the addition of (final Core-Q module, subunits responsible for the electron transfer to ubiquinone; Core-N module, subunits responsible for the oxidation of NADH; Supernumerary subunits-those that are additional to the core subunits required for the catalytic role of complex I, but do not play a catalytic role themselves. Many of these subunits may be performing a structural role, but the majority are of unknown function. The supernumerary subunits can be further subdivided into supernumerary -N module, those accessory subunits associated with the NADH oxidation module of CI; supernumerary ACP (acyl carrier protein) -in addition to being a non-catalytic subunit of CI, NDUFAB1 is also a carrier of the growing fatty acid chain in mitochondrial fatty acid biosynthesis; assembly factor, proteins that are required for the correct assembly and integration of CI. ( 
d) Overexpression of
Cerox1 results in large increases in the total protein levels of two core subunits NDUFS1 (average densitometry 1.92, P = 0.0043) and NDUFS3 (average densitometry 2.14, P = 0.013) for which high quality antibodies exist, normalised to the loading control -tubulin (TUBA1A). NDUFS1 is one of MREs whose presence is conserved in both the mouse and human Cerox1. Coloured MREs indicate those MREs whose presence is conserved between mouse and human and whose miRNAs are expressed in N2A cells. miRNA site types are as follows: miR-28-5p, 8mer-A1; miR-138-5p, 6mer;
miR-370-3p, 7mer-m8; miR-488-3p-3p, 7mer-m8; miR-708-5p, 7mer-A1. The grey predicted MREs represent those that are conserved, but whose miRNAs are not expressed in N2A cells (miR-125a-3p, Table 2 ).
Due to known widespread noncanonical miRNA binding [80] , predictions were also extended across the gene body (bracketed MREs). 
